- ongoing, recruitingTherapeutic exploratory (Phase II)
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)
This study looks at a new medicine called felzartamab for people with a kidney condition called membranous nephropathy, who haven't improved with other treatments. It aims to see if the new medicine can reduce protein in their urine and help their kidneys get better.
Italy - recruiting
Nephrotic Syndrome Study Network
This study aims to better understand rare kidney diseases like Minimal Change Disease, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy. It collects information and samples to help researchers find better treatments, as current ones have many side effects and don't always work.
United States · Canada - recruitingPHASE3
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
This study looks at treating a kidney disease called membranous nephropathy. It uses a medicine called rituximab, but personalises the dose with AI to help more people respond well and reduce kidney damage.
France - recruiting
National Registry of Rare Kidney Diseases
This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.
United Kingdom